NHLBI Clinical Ancillary Studies (R01 - Clinical Trial Optional) | PAR 18 643

Opportunity Information: Apply for PAR 18 643

The NHLBI Clinical Ancillary Studies (R01 - Clinical Trial Optional) funding opportunity (PAR-18-643) is a National Institutes of Health discretionary grant designed to speed up and broaden research on the clinical course, prevention, and treatment of conditions that fall within the National Heart, Lung, and Blood Institute (NHLBI) mission. The central idea is to get more scientific value out of studies that are already underway by supporting ancillary studies, meaning add-on projects that build on an existing "parent" clinical research study rather than starting a brand-new cohort or trial from scratch.

This FOA invites R01 research project grant applications proposing ancillary studies that attach to ongoing clinical research efforts such as clinical trials, prospective observational studies, and registries. To fit the announcement, the proposed ancillary work must collect new information and/or new biological samples from people who are already participants in the parent study. Just as importantly, the ancillary study must ask and answer new research questions that go beyond what is already laid out in the parent study's approved protocol. In other words, applicants are expected to leverage the existing infrastructure, participant group, and follow-up already in place, but the science itself must be clearly distinct, additive, and within NHLBI's scientific scope.

The announcement also draws clear boundaries around what the funds can and cannot be used for. These awards are not meant to extend the duration of the parent study, and they cannot be used simply to pay for parent study enrollment, capitation payments, or routine study performance costs. The expectation is that the parent study is already funded and moving forward, and the ancillary award covers the incremental work needed to answer the new questions, such as additional measurements, specimen collection, specialized assays, extra data elements, or other new data capture that was not included in the original study plan.

Eligible applicants span a wide range of organizations typically allowed under NIH research grant policies. This includes state, county, and local governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; other Native American tribal organizations; public housing authorities/Indian housing authorities; nonprofits with and without 501(c)(3) status; for-profit organizations (other than small businesses); and small businesses. The FOA explicitly highlights additional eligible applicant categories such as Alaska Native and Native Hawaiian Serving Institutions, AANAPISI institutions, Hispanic-serving institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), eligible federal agencies, and faith-based or community-based organizations, as well as regional organizations and U.S. territories or possessions.

On the foreign eligibility side, the FOA makes a distinction between foreign institutions and foreign involvement. Non-domestic (non-U.S.) entities (foreign institutions) are not eligible to apply as the applicant organization. However, non-domestic components of U.S. organizations may participate, and foreign components (as NIH defines them in the NIH Grants Policy Statement) are allowed, meaning the research can include certain types of international collaboration or work conducted abroad as part of a U.S.-led application, as long as it follows NIH policy and the FOA's terms.

The opportunity is administered by NIH and falls under multiple CFDA listings, including 93.233 and 93.837 through 93.840, reflecting its alignment with NIH/NHLBI research funding authorities. The listing includes an award ceiling of $250,000, indicating an upper cap referenced in the opportunity information. The original closing date shown in the source data is January 23, 2020, and the FOA creation date is February 8, 2018, which situates the announcement historically as a published NIH program announcement for ancillary studies rather than a one-time standalone competition.

• The National Institutes of Health in the health sector is offering a public funding opportunity titled "NHLBI Clinical Ancillary Studies (R01 - Clinical Trial Optional)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.233, 93.837, 93.838, 93.839, 93.840.
• This funding opportunity was created on 2018-02-08.
• Applicants must submit their applications by 2020-01-23. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $250,000.00 in funding.
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for PAR 18 643

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: